EMR Stock Analysis: Emerson Electric | NYSE
Specialty Industrial Machinery | NYSE, USA | Market Cap: 80.173m USD | 12M Return: 8.9% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 398M
EPS Trend: 96.4%
Qual. Beats: 0
Rev. Trend: 90.6%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 10.5 years of data
Average return per month, with how dependable it is below — did the month move the same way every year (high) or randomly (low). Above 60 is a pattern worth trusting; under 40 is noise.
Emerson Electric Co. (EMR) is a global technology and software company headquartered in Saint Louis, Missouri, that provides industrial automation, process control, and measurement solutions across the Americas, Asia, the Middle East, Africa, and Europe. The company operates through six business segments-Final Control, Measurement & Analytical, Discrete Automation, Safety & Productivity, Control Systems & Software, and Test & Measurement-offering products such as control valves, intelligent instrumentation, solenoid and pneumatic valves, process control software (DeltaV and Ovation), professional and consumer tools, and automated test systems. Emerson serves a diverse customer base spanning process industries (oil & gas, chemicals, power), discrete manufacturing, and infrastructure, marketing under well-known brands such as Fisher, Rosemount, ASCO, Branson, and RIDGID.
Listed on the NYSE as a Large Cap stock in the Industrials sector (Electrical Components & Equipment sub-industry), Emerson has been in operation since its incorporation in 1890, giving it more than 130 years of industrial heritage. The companys business model combines hardware products (valves, instruments, tools) with higher-margin software and automation solutions, an increasingly important strategic focus as manufacturers and process operators pursue digitalization and operational efficiency.
- Process automation demand tracks energy and chemicals capital spending
- Test and Measurement segment benefits from AI data center infrastructure investment
- AspenTech and DeltaV software expand recurring revenue mix and margins
| Net Income: 2.44b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.07 > 0.02 and ΔFCF/TA 0.82 > 1.0 |
| NWC/Revenue: -7.66% < 20% (prev -12.60%; Δ 4.94% < -1%) |
| CFO/TA 0.08 > 3% & CFO 3.56b > Net Income 2.44b |
| Net Debt (13.0b) to EBITDA (5.14b): 2.52 < 3 |
| Current Ratio: 0.87 > 1.5 & < 3 |
| Outstanding Shares: last quarter (563.0m) vs 12m ago -0.42% < -2% |
| Gross Margin: 52.66% > 18% (prev 52.77%; Δ -0.11% > 0.5%) |
| Asset Turnover: 43.58% > 50% (prev 41.94%; Δ 1.63% > 0%) |
| Interest Coverage Ratio: 6.16 > 6 (EBIT TTM 3.66b / Interest Expense TTM 594.0m) |
| A: -0.03 (Total Current Assets 9.25b - Total Current Liabilities 10.7b) / Total Assets 42.1b |
| B: 0.98 (Retained Earnings 41.2b / Total Assets 42.1b) |
| C: 0.09 (EBIT TTM 3.66b / Avg Total Assets 42.0b) |
| D: 0.93 (Book Value of Equity 20.3b / Total Liabilities 21.8b) |
| Altman-Z'' = 4.54 = AA |
| DSRI: 1.05 (Receivables 3.16b/2.90b, Revenue 18.3b/17.6b) |
| GMI: 1.00 (GM 52.77% / 52.66%) |
| AQI: 0.98 (AQ_t 0.71 / AQ_t-1 0.73) |
| SGI: 1.04 (Revenue 18.3b / 17.6b) |
| TATA: -0.03 (NI 2.44b - CFO 3.56b) / TA 42.1b) |
| Beneish M = -2.97 (Cap -4..+1) = A |
As of June 30, 2026, the stock is trading at USD 142.82 with a total of 2,277,937 shares traded. Over the past week, the price has changed by -4.92%, over one month by -0.70%, over three months by +16.30% and over the past year by +8.86%.
Current recommended Stop Loss: 137.10 (which is 4% or 1.3 ATR below the current price).
Emerson Electric has received a consensus analysts rating of 4.27. Therefore, it is recommended to buy EMR.
- StrongBuy: 19
- Buy: 3
- Hold: 6
- Sell: 1
- StrongSell: 1
| Analysts Target Price | 163.5 | 14.5% |
P/E Trailing = 33.1343
P/E Forward = 19.9601
P/S = 4.3772
P/B = 3.9488
P/EG = 1.995
Revenue TTM = 18.3b USD
EBIT TTM = 3.66b USD
EBITDA TTM = 5.14b USD
Long Term Debt = 7.55b USD (from longTermDebt, last quarter)
Short Term Debt = 5.95b USD (from shortTermDebt, last quarter)
Debt = 14.8b USD (from shortLongTermDebtTotal, last quarter) + Leases 698.0m
Net Debt = 13.0b USD (calculated: Debt 14.8b - CCE 1.79b)
Enterprise Value = 93.1b USD (80.2b + Debt 14.8b - CCE 1.79b)
Interest Coverage Ratio = 6.16 (Ebit TTM 3.66b / Interest Expense TTM 594.0m)
EV/FCF = 29.90x (Enterprise Value 93.1b / FCF TTM 3.12b)
FCF Yield = 3.34% (FCF TTM 3.12b / Enterprise Value 93.1b)
FCF Margin = 17.01% (FCF TTM 3.12b / Revenue TTM 18.3b)
Net Margin = 13.35% (Net Income TTM 2.44b / Revenue TTM 18.3b)
Gross Margin = 52.66% ((Revenue TTM 18.3b - Cost of Revenue TTM 8.67b) / Revenue TTM)
Gross Margin QoQ = 53.09% (prev 53.18%)
Tobins Q-Ratio = 2.21 (Enterprise Value 93.1b / Total Assets 42.1b)
Interest Expense / Debt = 4.03% (Interest Expense 594.0m / Debt 14.8b)
Taxrate = 21.24% (658.0m / 3.10b)
NOPAT = 2.88b (EBIT 3.66b * (1 - 21.24%))
Current Ratio = 0.87 (Total Current Assets 9.25b / Total Current Liabilities 10.7b)
Debt / Equity = 0.73 (Debt 14.8b / totalStockholderEquity, last quarter 20.3b)
Debt / EBITDA = 2.52 (Net Debt 13.0b / EBITDA 5.14b)
Debt / FCF = 4.16 (Net Debt 13.0b / FCF TTM 3.12b)
Total Stockholder Equity = 20.2b (last 4 quarters mean from totalStockholderEquity)
RoA = 5.82% (Net Income 2.44b / Total Assets 42.1b)
RoE = 12.11% (Net Income TTM 2.44b / Total Stockholder Equity 20.2b)
RoCE = 13.20% (EBIT 3.66b / Capital Employed (Equity 20.2b + L.T.Debt 7.55b))
RoIC = 7.91% (NOPAT 2.88b / Invested Capital 36.5b)
WACC = 10.09% (E(80.2b)/V(94.9b) * Re(11.36%) + D(14.8b)/V(94.9b) * Rd(4.03%) * (1-Tc(0.21)))
Discount Rate = 11.36% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -68.89 | Cagr: -0.80%
[DCF] Terminal Value 72.15% ; FCFF base≈2.97b ; Y1≈3.34b ; Y5≈4.69b
[DCF] Fair Price = 73.80 (EV 54.3b - Net Debt 13.0b = Equity 41.3b / Shares 560.1m; r=10.09% [WACC]; 5y FCF grow 12.78% → 2.50% )
EPS Correlation: 96.35 | EPS CAGR: 12.03% | SUE: 0.23 | # QB: 0
Revenue Correlation: 90.60 | Revenue CAGR: 6.02% | SUE: -0.54 | # QB: 0
EPS current Year (2026-09-30): EPS=6.51 | Chg30d=+0.03% | Revisions=+30% | GrowthEPS=+8.4% | GrowthRev=+4.6%
EPS next Year (2027-09-30): EPS=7.17 | Chg30d=+0.20% | Revisions=+10% | GrowthEPS=+10.2% | GrowthRev=+5.5%
[Analyst] Revisions Ratio: +30%